詳細検索はこちら

加藤 友久 カトウ トモヒサ

所属部署名先端医療研究領域, 総合医学研究所
職名講師
 
 

研究者基本情報

学歴

  • 京都大学 大学院 医学研究科

学位

  • 博士(医学)

研究活動情報

論文

  • Clinical trial on the safety and tolerability of personalized cancer vaccines using human platelet lysate-induced antigen-presenting cellsTerutsugu Koya, Kenichi Yoshida, Misa Togi, Yo Niida, Sumihito Togi, Hiroki Ura, Shuichi Mizuta, Tomohisa Kato Jr, Sohsuke Yamada, Takeo Shibata, Yi-Chang Liu, Shyng-Shiou Yuan, Deng-Chyang Wu, Hirohito Kobayashi, Taiju Utsugisawa, Hitoshi Kanno, Shigetaka ShimodairaCancers15:36272023年07月
  • Expandable Sendai-virus-reprogrammed human iPSC-neuronal precursors: In vivo post-grafting safety characterization in rats and adult pigKobayashi Y, Shigyo M, Platoshyn O, Marsala S, Kato T Jr, Takamura N, Yoshida K, Kishino A, Bravo-Hernandez M, Juhas S, Juhasova J, Studenovska H, Proks V, Driscoll SP, Glenn TD, Pfaff SL, Ciacci JD, Marsala MCell Transplanttion32:096368972211070092023年04月
  • Derivation of Sendai-virus-reprogrammed human iPSCs-neuronal precursors: In vitro and in vivo post-grafting safety characterizationShigyo M, Kobayashi Y, Platoshyn O, Marsala S, Kato T Jr, Takamura N, Yoshida K, Kishino A, Bravo-Hernandez M, Juhas S, Juhasova J, Studenovska H, Proks V, Ciacci JD, Marsala MCell Transplantation32:96368972311632302023年03月
  • Selective vulnerability of human-induced pluripotent stem cells to dihydroorotate dehydrogenase inhibition during mesenchymal stem/stromal cell purificationAl-Akashi Z, Zujur D, Kamiya D, Kato T Jr, Kondo T, Ikeya MFrontiers in Cell and Developmental Biology11:10899452023年02月
  • The Detection of Immunity against WT1 and SMAD4P130L of EpCAM+ Cancer Cells in Malignant Pleural EffusionTerutsugu Koya, Yo Niida, Misa Togi, Kenichi Yoshida, Takuya Sakamoto, Hiroki Ura, Sumihito Togi, Tomohisa Kato Jr, Sohsuke Yamada, Haruo Sugiyama, Shigeo Koido, Shigetaka ShimodairaInternational Journal of Molecular Sciences23:121772022年10月
  • Different in vitro-generated MUTZ-3-derived dendritic cell types secrete dexosomes with distinct phenotypes and antigen presentation potencies.Sakamoto T, Koya T, Togi M, Yoshida K, Kato T Jr, Ishigaki Y, Shimodaira S.International Journal of Molecular Sciences11:83622022年07月
  • Mapping the hotspots for DNA repair synthesis in human brain organoids.Kato T Jr, Muotri AR.Cell Death & Differentiation28:3193-31952021年08月
  • Quality Verification with a Cluster-Controlled Manufacturing System to Generate Monocyte-Derived Dendritic CellsHaruhiko Kawaguchi, Takuya Sakamoto, Terutsugu Koya, Misa Togi, Ippei Date, Asuka Watanabe, Kenichi Yoshida, Tomohisa Kato, Yuka Nakamura, Yasuhito Ishigaki, Shigetaka ShimodairaVaccines9:5332021年05月
  • Identification of CD56 dim subpopulation marked with high expression of GZMB/PRF1/PI-9 in CD56 + interferon-α-induced dendritic cellsAsuka Watanabe, Misa Togi, Terutsugu Koya, Makoto Taniguchi , Takuya Sakamoto, Kuniyoshi Iwabuchi, Tomohisa Kato, Shigetaka ShimodairaGenes to cells26:313-3272021年05月
  • Interferon-α-Induced Dendritic Cells Generated with Human Platelet Lysate Exhibit Elevated Antigen Presenting Ability to Cytotoxic T LymphocytesDate I, Koya T, Sakamoto T, Togi M, Kawaguchi H, Watanabe A, Kato T Jr, Shimodaira SVaccines9:102021年
  • Dendritic Cells Pre-Pulsed With Wilms' Tumor 1 in Optimized Culture for Cancer VaccinationTerutsugu Koya, Ippei Date, Haruhiko Kawaguchi, Asuka Watanabe, Takuya Sakamoto, Misa Togi, Tomohisa Kato Jr, Kenichi Yoshida, Shunsuke Kojima, Ryu Yanagisawa, Shigeo Koido, Haruo Sugiyama , Shigetaka ShimodairaPharmaceutics12:3052020年03月
  • In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer VaccinationShimodaira S, Yanagisawa R, Koya T, Hirabayashi K, Higuchi Y, Sakamoto T, Togi M, Kato T Jr, Kobayashi T, Koizumi T, Koido S, Sugiyama HVaccines (Basel)7:1202019年09月

書籍等出版物

  • ミニブタにおける同系および同種iPSC由来の神経前駆細胞の脊髄への移植後の生存について
    Japanese Scientists in Science Translational Medicine 2018
    加藤 友久, Martin Marsala
    American Association for the Advancement of Science (AAAS) 2019年03月

競争的資金

  • 筋萎縮性側索硬化症(ALS)に対する遺伝子治療法の開発
    日本医療研究開発機構(AMED):AMED研究費 分担研究 難治性疾患実用化研究事業
    研究期間:2020年 - 2022年  
    代表者:井上 治久(京都大学iPS細胞研究所)分担・連携研究者:加藤 友久